Prescribing antipsychotic drugs for inpatients with schizophrenia in Asia: Comparison of REAP-2001 and REAP-2004 studies

Asia-Pacific Psychiatry

Volumn 2, Issue 2, 2010, Pages 77-84

  Chong, Mian Yoon ^a   Tan, Chay Hoon ^b   Shinfuku, Naotaka ^c   Yang, Shu Yu ^d   Sim, Kang ^e   Fujii, Senta ^f   Si, Tianmei ^g   Chung, Eun Kee ^h   Kua, Ee Heok ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Seinan Gakuin University   (Japan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e INSTITUTE OF MENTAL HEALTH   (Singapore)

^f Hyogo Institute for Traumatic Stress   (Japan)

^g PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^h SOUTHWEST UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antipsychotic prescription; Antipsychotic utilization; Inpatient schizophrenia treatment; Pharmacoepidemiology

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PEROSPIRONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; ZIPRASIDONE; ZOTEPINE;

ADULT; ARTICLE; ASIA; CHINA; CONTROLLED STUDY; DRUG MEGADOSE; DRUG USE; FEMALE; HONG KONG; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; JAPAN; KOREA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SINGAPORE; TAIWAN; TREND STUDY;

EID: 77953464815     PISSN: 17585864     EISSN: 17585872     Source Type: Journal    
DOI: 10.1111/j.1758-5872.2010.00068.x     Document Type: Article

References (35)

1. American Psychiatric Association. (1994) Diagnostic and Statistical Manual of Mental Disorder, 4th ed. American Psychiatric Press
2. Bergnab U., Grimsson A., Wahba A.H.W., Westerholm B. (1979) Studies in Drug Utilization (European Series 8). WHO Regional Office for Europe
3. Bowers L., Callangan P., Clark N., Evers C. (2004) Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe. Eur J Clin Pharmacol. 60, 29 35.
4. Buchanan R.W., Kreyenbuhl J., Zito J.M., Lehman A. (2002) The schizophrenia PORT pharmacological treatment recommendations: conformance and implications for symptoms and functional outcome. Schizophr Bull. 28, 63 73.
5. Chong M.Y. (2008) Psychopharmacoepidemiology: scope and application. Taiwan J Psychiatry. 22, 3 15.
6. Chong M.Y., Tan C.H., Fujii S., et al 2004) Antipsychotic drug prescription for schizophrenia in East Asia: a rationale for change. Psychiatr Clin Neurosci. 58 (1), 61 67.
7. Chong S.A., Sachdev P., Mahendran R., et al 2000) Neuroleptic and anticholinergic drug use in Chinese patient with schizophrenia resident in a state psychiatric hospital in Singapore. Aust NZ J Psychiatry. 34, 988 991.
8. Christensen D.B., Bush P.J. (1981) Drug prescribing: pattern, problems and proposals. Soc Sci Med. 15, 343 355.
9. Hemminki E. (1975) Review of literature on the factors affecting drug prescribing. Soc Sci Med. 9, 111 115.
10. Hemminki E. (1988) Factors influencing prescribing. In : Psychoactive Drugs: Improving Prescribing Practices (eds Ghodse H., Khan I. pp. 22 35. WHO
11. Hennessy S., Strom B.L., Lipton H., Soumerai S.B. (2000) Drug utilization review. In : Pharmacoepidemiology (3rd ed, eds Strom B.L. pp. 505 523. John Wiley and Sons Ltd
12. Inagaki A., Inada T., Fujii Y., Yagi G. (2001) Dose equivalence of psychotropic drugs. Part XV - dose equivalence of novel neuroleptics. Perospirone. Jap Clin Psychopharmacol. 4, 869 870.
13. Ito C., Kubota Y., Sato M. (1999) A prospective survey on drug choice for prescription for admitted patients with schizophrenia. Psychiat Clin Neurosci. 53 (Suppl 1), 535 540.
14. Kane J.M., Aguglia E., Altamura A.C., et al 1998) Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol. 8, 55 66.
15. Lasgna L. (1974) A plea for the naturalistic study of medicines. Eur J Clin Pharmacol. 7, 153 154.
16. Lelliott P., Paton C., Harrington M., Konsolaki M., Sensky T., Okocha C. (2002) The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull. 26, 411 414. (Pubitemid 35331237)
17. Leucht S., Conves C., Arbter D., Engel R.R., Li C., Davis J.M. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 373, 31 41.
18. Lunde P.K.M., Baksaas I. (1988) Epidemiology of drug utilization - basic concepts and methodology. Acta Med Scand Suppl. 721, 7 11.
19. McCue R.E., Waheed R., Urcuyo L. (2003) Polypharmacy in patients with schizophrenia. J Clin Psychiatry. 64, 984 989.
20. Miller A.L., Craig C.S. (2002) Combination of antipsychotics: pros, cons, and questions. Schizophr Bull. 28, 105 109.
21. Rothbard A.B., Kuno E., Foley K. (2003) Trend in the rate and type of antipsychotic medications prescribed to persons with schizophrenia. Schizophr Bull. 29 (3), 531 540.
22. Sartorius N., Fleischhacker W.W., Gjerris A., et al 2002) The usefulness and use of second-generation antipsychotic medications. Curr Opin Psychiatry. 15 (Suppl), 1 51.
23. Schumacher J.E., Makela E.H., Griffin H.R. (2003) Multiple antipsychotic medication prescribing patterns. Ann Pharmacother. 37, 951 955.
24. Shiloh R., Nutt D., Weizman A. (2000) Atlas of Psychiatric Pharmacotherapy, Revised edition. Martin Dunitz
25. Sim K., Su A., Fujii S., et al 2004a) Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol. 58 (2), 178 183.
26. Sim K., Su A., Leong J.Y., et al 2004b) High dose antipsychotic use in schizophrenia: research on East Asia psychotropic prescription (REAP) findings. Pharmacopsychiatry. 37 (4), 175 179.
27. Sim K., Su A., Ungvari G., et al 2004c) Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol Clin Exp. 19 (1), 103 109.
28. Tap A., Wood E., Secrest L., Erdmann J., Cubberley L., Kilzieh N. (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 54, 55 59.
29. Westerholm B. (1986) Therapeutic auditing at the national and international level. Br J Clin Pharmacol. 22, 555 598.
30. WHO Collaborating Centre for Drug Statistic Methodology. (2002) Guidelines for ATC Index with DDDs. WHO
31. WHO Expert Committee. (1977) The Selection of Essential Drugs (Technical Report Series 615). World Health Organization
32. Woods S.W. (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 64, 663 667.
33. World Health Organization. (1992) The ICD Classification of Mental and Behavioral Disorder. Clinical Description and Diagnostic Guidelines. WHO
34. Yang S.Y., Kao Yang Y.H., Chong M.Y., Yang Y.H., Chang W.H., Lai C.S. (2006) Risk of extrapyrimidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol. 81, 586 594.
35. Yoshimura R., Okamoto T., Nakamura J., et al 2006) Prescription pattern of antipsychotic drugs for schizophrenic inpatients in Japan: research on East Asia psychotropic prescription pattern - antipsychotics study. Psychiat Clin Neurosci. 60 (6), 778 779.